Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Femasys Inc.

< Previous 1 2 Next >
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY PMCB
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. EU MDR Final Audit Successfully Completed
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. MDSAP Surveillance Audit Successfully Completed
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Obtains Medical Device Establishment License from Health Canada
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.